With news developing daily about COVID-19 vaccines, Hoag is dedicated to providing the community with the most up-to-date information and access to innovative treatment options.
Selected as an approved provider of COVID-19 vaccines, Hoag is involved in the continued research and planned distribution for how to support both our health care workers and the community as vaccines become available.
Since March, Hoag has conducted more than 20 COVID-19 clinical trials to expand patient access to cutting-edge therapies, including being selected as the first in the nation to offer a trial for a novel COVID-19 vaccine candidate being developed here in Southern California in partnership with NantKwest and ImmunityBio.
Hoag was chosen based on its comprehensive center for research and education, as well as the hospital’s commitment to excellence and the communities it serves. As a trusted partner in health and wellness, Hoag is proud to work together for the greater good to fight this disease.
For more information, visit hoag.org/COVID.
